Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × VAP-cyclo protocol × Clear all
NCT05963347 2023-09-01

Go-CHOP as the Frontline Therapy for PTCL

Henan Cancer Hospital

Phase 2 Recruiting
45 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡